Golimumab

Related products

• 

  Multiple sclerosis , Rheumatoid arthritis (RA)

  Pirfenidone

  【Product name】Pirfenex, Esbriet

  [English common name]Pirfenidone

  [Chinese common name]Pirfenidone

  [English name]

  [Chinese other name]

  [indications]
  1. Idiopathic pulmonary fibrosistranssexual
  Idio-pathic pulmonary fibrosis (IPF) is a chronic inflammatory interstitial lung disease with unknown causes, poor prognosis, and high mortality. PFD is an anti-inflammatory, anti-fibrotic preparation that can be used in the treatment of IPF.
  2. Liver fibrosis
  3. Renal fibrosis
  4.Multiple sclerosis
  Multiple sclerosis (MS) is an inflammation and demyelinating disease associated with the central nervous system and immunity. The immune factors associated with it are the activation of stellate cells, glia cells, endothelial cells and the increase of lymphocytes, while PFD has the property of inhibiting cell activation.
  5. Myocardial tissue fibrosis
  Cardiovascular diseases such as hypertension, cardiomyopathy, and atrial fibrillation can cause fibrosis of myocardial tissue, which in turn can worsen or develop the disease. Treatment of progressive pseudohypertrophic muscular dystrophy with PFDcardiac diseaseIt can inhibit myocardial fibrosis and improve heart function. PFD reduces myocardial remodeling and atrial fibrillation by inhibiting fibrosis.
  6. Neoplastic diseases:Neurofibroma, uterine leiomyoma, malignant glioma.
  7. Prevention of fibrosis after organ transplantation
  8.Rheumatoid arthritis

  [Usage and Dosage] This product gradually increases the dosage according to the principle of increasing dose. When taking this product on an empty stomach, the concentration of pirfenidone in the blood will increase significantly, and side effects may occur, so it is appropriate to take it after meals. The initial dosage of this product is 200mg each time, 3 times a day. It is hoped that by increasing the dose of 200mg every time in two weeks, the dosage of this product will be maintained at 600mg (1800mg per day); it should be closely observed. Patients with medication tolerance, if there are obvious gastrointestinal symptoms, skin reactions to sunlight or UV light, significant changes in liver function enzymes and weight loss, you can reduce the dose according to clinical symptoms or stop taking the drug, in the symptoms After the reduction, the dosage can be gradually increased, and it is preferable to adjust the maintenance amount to 400 mg (1200 mg per day) or more.

  [Storage] Store at 15-30 ° C; (59-86 ° F).

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Rheumatoid arthritis (RA)

  Tofatinib

  【Product name】Xeljanz

  [English common name]Tofacitnib

  [Chinese common name]Tofatinib

  [English name]

  [Chinese other name]

  [Indications] XELJANZ, an inhibitor of Janus kinase (JAKs), is indicated for the treatment of moderate to severe activityRheumatoid arthritisAdult patients have not responded well or are intolerant to methotrexate. It can be used as a monotherapy or in combination with methotrexate or other non-biological disease modifying antirheumatic drugs (DMARDs). XELJANZ should not be combined with biological products DMARD or strong immunosuppressive agents such as azathioprine and cyclosporine.

  [Usage and dosage] rheumatoid arthritis
  Tofacinix can be used in combination with methotrexate or other non-biological DMARD drugs. The recommended dose for Tofacinix is 5 mg twice daily. Oral administration, with or without food.
  Dose adjustment for severe infection and cytopenia is not recommended in patients with absolute lymphocyte counts below 500 cells/mm3, absolute neutrophil counts (ANC) below 1000 cells/mm3, or hemoglobin levels below 9 g/dL. Start Tofacinix medication.
  In the case of lymphopenia, neutropenia, and anemia, it is recommended to adjust the dose or discontinue treatment.[See notes and adverse reactions]
  If the patient has a serious infection, Tofacinix should be avoided until the infection is controlled.
  Dose adjustment due to drug interactions in the following patients:
  It is also treated with a potent inhibitor of cytochrome P450 3A4 (CYP3A4) (such as ketoconazole) or one or more combined drugs (such as fluconazole) that can cause both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19. The recommended dose for Tofacinix should be 5 mg once daily.
  Combinations of Tofacinix with potent CYP3A4 inducers (such as rifampicin) may result in loss or decline in clinical remission. A potent CYP3A4 inducer is not recommended for combination with Tofacinix.
  Dosing adjustment for patients with renal or hepatic impairment
  Among the following patients:
  Moderate or severe renal insufficiency, or moderate liver damage, Tofacinix recommended dose should be 5 mg once daily. Tofacinix is not recommended for patients with severe liver damage.

  [Storage]Store in a cool dry place, no more than 30 ° C. Protect from light and avoid contact with children.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Rheumatoid arthritis (RA)

  Tombuzumab

  【Product name】ACTEMRA

  [English common name]TocilizumabInjection

  [Chinese common name]Tocilizumab injection

  [English name]Tocilizumab

  [Chinese other name]

  [Indications] for moderate to severe-activity of poor response to one or more TNF antagonistsRheumatoid arthritisAdult patient.

  [Usage and dosage] Rheumatoid arthritis. ACTEMRA can be used alone or in combination with methotrexate or other DMARDs.
  1. Adult recommended dose every 4 weeks: Patients do not respond well to one or more TNF antagonists: when used in combination with DMARD or monotherapy, the recommended starting amount is 4 mg/kg and then increased to 8 based on clinical response. Mg/kg. Patients with neutrophil absolute count (ANC) below 2000/mm3, platelet counts below 100,000/mm3, or ALT or AST above 1.5 times the upper limit of normal (ULN) are advised not to start with ACTEMRA.
  2. It is recommended that the dose of ACTEMRA should not exceed 800 mg per infusion.
  3. Administration for intravenous infusion is diluted with sterile to 100 mL of 0.9% sodium chloride. A single intravenous drip during 1 hour. Don't push.
  4. Adjust dose recommendations for certain dose-related laboratory changes including elevated liver enzymes, leukopenia, and thrombocytopenia.

  [Storage] Store in the refrigerator (2 ° C - 8 ° C). Do not freeze. Place the pre-installed syringe in the outer carton to prevent light and moisture.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.
• 

  Rheumatoid arthritis (RA)

  Celecoxib

  [product name] Celebrex

  [English common name] Celecoxib

  [Chinese common name] celecoxib

  [English name]

  [Chinese other name]

  [indications]The potential benefits and risks of this product and other treatment options should be carefully considered before deciding to use this product. The minimum effective dose is used within the shortest treatment time, based on the treatment goals of each patient.
  (1) It is used to relieve the symptoms and signs of osteoarthritis.
  (2) for relieving adultsRheumatoid ArthritisSymptoms and signs.
  (3) for the treatment of acute pain in adults.

  [Usage and Dosage] Before deciding to use this product, you should carefully consider the potential benefits and risks of this product and other treatment options. The minimum effective dose is used within the shortest treatment time, based on the treatment goals of each patient.
  Osteoarthritis and rheumatoid arthritis, the lowest dose of this product is determined according to individual conditions. The time of eating has no effect on the dose used.
  Osteoarthritis: This product relieves the symptoms and signs of osteoarthritis. The recommended dose is 200mg, once daily or 100mg twice daily.
  Rheumatoid arthritis: This product relieves the symptoms and signs of rheumatoid arthritis. The recommended dose is 100mg to 200mg twice daily.
  Acute pain: The recommended dose is 400mg on the first day of the first dose, if necessary, can be taken 200mg; then, as needed, twice daily, 200mg each time.
  Special population
  Patients with impaired liver function: The recommended daily dose of this product should be reduced by approximately 50% in patients with moderate hepatic impairment (Child-Pugh II). This product is not recommended for patients with severe liver function impairment.

  [Storage]Sealed and stored below 25°C.

  [Tips] Some of the information on this site comes from the Internet and is only used internally by pharmacists or medical staff. It is not a substitute for doctors to diagnose face to face. Please consult a professional pharmacist for specific medications. Please refer to the actual product manual or the actual product for the product content.